BNBX logo

BNB PLUS CORP

BNBXNASDAQ
🏆 #5437 by market capUS Equity
$0.16▼ $0.08 (−52.64%)
Live
🔔
Track BNBX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 52.6%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
ytd▼ 87.2%
1y▼ 97.4%
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
-44.8%
Declining
📊Gross Margin
46.8%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
0.4x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$0.16 – $0.16
52-Week Range
$0.07 – $7.15
Volume
$2.66B
Avg Volume
$1.96B
Shares Outstanding
7.2M
Next Earnings
Oct 18, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
0.4x
EPS (TTM)
$-15.47
Dividend Yield
—

Why Investors Own BNBX

  • ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BNBX logo

BNB PLUS CORP

BNBX
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$2M▼ −14.0% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
47.3%▲ +3.5% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$670,998▼ −14.0% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$367,553▼ −14.0% YoY
StockOtter · stockotter.space

About BNB PLUS CORP

BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$0.16
▼ −1.1% Downside
High Target$0.18
Low Target$0.14
Based on 17 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

BNB PLUS CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift BNBX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

BNB PLUS CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.